Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
Traws Pharma announced its Q2 2026 financial results, highlighting progress in advancing tivoxavir marboxil towards MHRA resubmission in Q3 2026 for its influenza challenge study, despite a U.S. FDA clinical hold. The company also detailed its April 2026 private placement, which secured $10 million …